HRP20050800A2 - Pharmaceutical compositions comprising a combination of rapamycin or its derivative and pimecrolimus for the treatment of inflammation- and immunologically-mediated diseases - Google Patents
Pharmaceutical compositions comprising a combination of rapamycin or its derivative and pimecrolimus for the treatment of inflammation- and immunologically-mediated diseasesInfo
- Publication number
- HRP20050800A2 HRP20050800A2 HR20050800A HRP20050800A HRP20050800A2 HR P20050800 A2 HRP20050800 A2 HR P20050800A2 HR 20050800 A HR20050800 A HR 20050800A HR P20050800 A HRP20050800 A HR P20050800A HR P20050800 A2 HRP20050800 A2 HR P20050800A2
- Authority
- HR
- Croatia
- Prior art keywords
- derivative
- treatment
- pharmaceutical compositions
- rapamycin
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0306070A GB0306070D0 (en) | 2003-03-17 | 2003-03-17 | Organic compounds |
GB0306868A GB0306868D0 (en) | 2003-03-25 | 2003-03-25 | Organic compounds |
GB0319226A GB0319226D0 (en) | 2003-08-15 | 2003-08-15 | Organic compounds |
PCT/EP2004/002714 WO2004082681A1 (fr) | 2003-03-17 | 2004-03-16 | Compositions pharmaceutiques comprenant une combinaison de rapamycine ou de son derive et de pimecrolimus pour le traitement de maladies inflammatoires et de maladies induites immunologiquement |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20050800A2 true HRP20050800A2 (en) | 2006-11-30 |
Family
ID=33032928
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20050800A HRP20050800A2 (en) | 2003-03-17 | 2005-09-12 | Pharmaceutical compositions comprising a combination of rapamycin or its derivative and pimecrolimus for the treatment of inflammation- and immunologically-mediated diseases |
Country Status (26)
Country | Link |
---|---|
US (1) | US20060154952A1 (fr) |
EP (1) | EP1608368B8 (fr) |
JP (1) | JP2006515017A (fr) |
KR (1) | KR100855140B1 (fr) |
AR (1) | AR043504A1 (fr) |
AT (1) | ATE409479T1 (fr) |
AU (1) | AU2004222563B2 (fr) |
BR (1) | BRPI0408423A (fr) |
CA (2) | CA2633287A1 (fr) |
CL (1) | CL2004000535A1 (fr) |
DE (1) | DE602004016830D1 (fr) |
EC (1) | ECSP056006A (fr) |
ES (1) | ES2315648T3 (fr) |
HK (1) | HK1086743A1 (fr) |
HR (1) | HRP20050800A2 (fr) |
IS (1) | IS8028A (fr) |
MA (1) | MA27671A1 (fr) |
MX (1) | MXPA05009934A (fr) |
MY (1) | MY137868A (fr) |
NO (1) | NO20054778L (fr) |
PE (1) | PE20050313A1 (fr) |
PL (1) | PL1608368T3 (fr) |
PT (1) | PT1608368E (fr) |
TN (1) | TNSN05197A1 (fr) |
TW (2) | TW200835484A (fr) |
WO (1) | WO2004082681A1 (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006050461A1 (fr) * | 2004-10-28 | 2006-05-11 | Wyeth | Utilisation d'un inhibiteur mtor dans le traitement de leiomyomes uterins |
AU2013205002B2 (en) * | 2008-03-21 | 2016-09-15 | The University Of Chicago | Treatment with opioid antagonists and mTOR inhibitors |
JP5647098B2 (ja) * | 2008-03-21 | 2014-12-24 | ザ ユニヴァーシティー オヴ シカゴ | オピオイド拮抗薬とmTOR阻害薬を用いた治療 |
JP5766124B2 (ja) | 2009-01-21 | 2015-08-19 | アムジェン インコーポレイテッド | 炎症性疾患および自己免疫疾患の処置の組成物および方法 |
RU2449806C1 (ru) * | 2010-11-30 | 2012-05-10 | Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" | Способ лечения красного плоского лишая слизистой оболочки полости рта |
DK2948134T3 (da) | 2013-01-24 | 2020-06-02 | Palvella Therapeutics Inc | Sammensætninger til transdermal indgivelse af mtor-inhibitorer |
AU2014332080B2 (en) | 2013-10-08 | 2020-02-27 | AI Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
NZ724756A (en) * | 2014-04-04 | 2023-07-28 | Ai Therapeutics Inc | An inhalable rapamycin formulation for treating age-related conditions |
AU2015330905B2 (en) | 2014-10-07 | 2021-02-25 | AI Therapeutics, Inc. | An inhalable rapamycin formulation for the treatment of pulmonary hypertension |
MY188430A (en) | 2015-04-10 | 2021-12-08 | Amgen Inc | Interleukin-2 muteins for the expansion of t-regulatory cells |
JP7108631B2 (ja) | 2017-01-06 | 2022-07-28 | パルヴェラ セラピューティクス、インク. | mTOR阻害剤の無水組成物およびその使用方法 |
EP3817743A4 (fr) | 2018-07-02 | 2022-07-06 | Palvella Therapeutics, Inc. | Compositions anhydres d'inhibiteurs de mtor et méthodes d'utilisation |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU640963B2 (en) * | 1989-11-09 | 1993-09-09 | MEDA Pharma S.a.r.l | Heteroatoms-containing tricyclic compounds |
GB9221220D0 (en) * | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
FR2736550B1 (fr) * | 1995-07-14 | 1998-07-24 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule |
DK1208847T3 (da) * | 1996-07-30 | 2007-01-08 | Novartis Ag | Farmaceutiske præparater til behandling af transplantatafstödning samt autoimmune eller inflammatoriske tilstande |
GB9723669D0 (en) * | 1997-11-07 | 1998-01-07 | Univ Aberdeen | Skin penetration enhancing components |
US20030119797A1 (en) * | 2001-05-09 | 2003-06-26 | Salah-Dine Chibout | Methods for selective immunomodulation |
RU2004124387A (ru) * | 2002-01-10 | 2005-06-10 | Новартис АГ (CH) | Системы введения лекарственных средств, содержащих рапамицин и его производные, которые предназначены для предупреждения и лечения сосудистых заболеваний |
IL164947A (en) * | 2002-05-09 | 2009-06-15 | Hemoteq Ag | Medical products comprising a haemocompatible coating and methods for their production |
-
2004
- 2004-03-08 AR ARP040100730A patent/AR043504A1/es not_active Application Discontinuation
- 2004-03-15 TW TW097116133A patent/TW200835484A/zh unknown
- 2004-03-15 PE PE2004000273A patent/PE20050313A1/es not_active Application Discontinuation
- 2004-03-15 TW TW093106848A patent/TW200503703A/zh unknown
- 2004-03-16 MX MXPA05009934A patent/MXPA05009934A/es not_active Application Discontinuation
- 2004-03-16 CL CL200400535A patent/CL2004000535A1/es unknown
- 2004-03-16 CA CA002633287A patent/CA2633287A1/fr not_active Abandoned
- 2004-03-16 BR BRPI0408423-3A patent/BRPI0408423A/pt not_active IP Right Cessation
- 2004-03-16 US US10/547,185 patent/US20060154952A1/en not_active Abandoned
- 2004-03-16 ES ES04720871T patent/ES2315648T3/es not_active Expired - Lifetime
- 2004-03-16 MY MYPI20040914A patent/MY137868A/en unknown
- 2004-03-16 JP JP2005518678A patent/JP2006515017A/ja active Pending
- 2004-03-16 CA CA002517671A patent/CA2517671A1/fr not_active Abandoned
- 2004-03-16 EP EP04720871A patent/EP1608368B8/fr not_active Expired - Lifetime
- 2004-03-16 PT PT04720871T patent/PT1608368E/pt unknown
- 2004-03-16 DE DE602004016830T patent/DE602004016830D1/de not_active Expired - Fee Related
- 2004-03-16 KR KR1020057017469A patent/KR100855140B1/ko not_active IP Right Cessation
- 2004-03-16 WO PCT/EP2004/002714 patent/WO2004082681A1/fr active IP Right Grant
- 2004-03-16 PL PL04720871T patent/PL1608368T3/pl unknown
- 2004-03-16 AT AT04720871T patent/ATE409479T1/de not_active IP Right Cessation
- 2004-03-16 AU AU2004222563A patent/AU2004222563B2/en not_active Ceased
-
2005
- 2005-08-17 TN TNP2005000197A patent/TNSN05197A1/en unknown
- 2005-09-08 EC EC2005006006A patent/ECSP056006A/es unknown
- 2005-09-12 HR HR20050800A patent/HRP20050800A2/xx not_active Application Discontinuation
- 2005-09-15 IS IS8028A patent/IS8028A/is unknown
- 2005-09-30 MA MA28526A patent/MA27671A1/fr unknown
- 2005-10-17 NO NO20054778A patent/NO20054778L/no not_active Application Discontinuation
-
2006
- 2006-06-13 HK HK06106761.8A patent/HK1086743A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP1608368B1 (fr) | 2008-10-01 |
TW200503703A (en) | 2005-02-01 |
US20060154952A1 (en) | 2006-07-13 |
JP2006515017A (ja) | 2006-05-18 |
PL1608368T3 (pl) | 2009-03-31 |
EP1608368A1 (fr) | 2005-12-28 |
AU2004222563B2 (en) | 2006-11-02 |
BRPI0408423A (pt) | 2006-03-21 |
MA27671A1 (fr) | 2005-12-01 |
ECSP056006A (es) | 2006-01-27 |
HK1086743A1 (en) | 2006-09-29 |
MY137868A (en) | 2009-03-31 |
IS8028A (is) | 2005-09-15 |
KR100855140B1 (ko) | 2008-08-28 |
ATE409479T1 (de) | 2008-10-15 |
CL2004000535A1 (es) | 2005-01-14 |
CA2633287A1 (fr) | 2004-09-30 |
MXPA05009934A (es) | 2006-03-21 |
CA2517671A1 (fr) | 2004-09-30 |
AU2004222563A1 (en) | 2004-09-30 |
ES2315648T3 (es) | 2009-04-01 |
WO2004082681A1 (fr) | 2004-09-30 |
EP1608368B8 (fr) | 2009-06-10 |
KR20050110023A (ko) | 2005-11-22 |
NO20054778L (no) | 2005-12-19 |
PT1608368E (pt) | 2009-01-27 |
PE20050313A1 (es) | 2005-06-14 |
NO20054778D0 (no) | 2005-10-17 |
WO2004082681B1 (fr) | 2004-11-25 |
TNSN05197A1 (en) | 2007-06-11 |
DE602004016830D1 (de) | 2008-11-13 |
AR043504A1 (es) | 2005-08-03 |
TW200835484A (en) | 2008-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20050800A2 (en) | Pharmaceutical compositions comprising a combination of rapamycin or its derivative and pimecrolimus for the treatment of inflammation- and immunologically-mediated diseases | |
ATE384061T1 (de) | Imidazo- und thiazolopyridine als jak3-kinase- inhibitoren | |
TW200718422A (en) | 1,6-Dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same | |
WO2007044050A3 (fr) | Composés tricycliques basés sur la 1h-imidazo[4,5-d]thiéno[3,2-b]pyridine et préparations pharmaceutiques les incluant | |
WO2004106293A3 (fr) | Composes tricycliques a base d'oxazolo[4,5-b]pyridine condensee a un imidazo et de thiazolo[4,5-b]pyridine condensee a un imidazo, et compositions pharmaceutiques renfermant ceux-ci | |
CY1109055T1 (el) | 11-((4r,6r)-4,5,6-τριϋδροξυ-3-(r)-υδροξυ-εξυλοκαρβαμοϋλο)-ενδεκαϊνικο οξυ | |
WO2008030744A3 (fr) | Inhibiteurs de c-met et leurs utilisations | |
ATE495743T1 (de) | Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten | |
ATE362932T1 (de) | Azaindolverbindungen als kinaseinhibitoren | |
EA200802058A1 (ru) | Производные циклоалкиламинокислот и их фармацевтические композиции | |
NO20084703L (no) | Triazolopyrazinforbindelser nyttige for behandling av degenerative og inflammatoriske sykdommer | |
WO2008107478A8 (fr) | Dérivés de quinolinone comme inhibiteurs de parp et de tank | |
NO20056192L (no) | Kapaseinhibitorer og anvendelse derav | |
WO2007084595A3 (fr) | Benzènesulfonyle-chromane, thiochromane, tétrahydronaphthalène et inhibiteurs de la gamma secrétase associés | |
CY1107747T1 (el) | Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης | |
ATE538124T1 (de) | Imidazokondensierte tricyclische verbindungen auf thiazoloä4,5-büpyridin-basis und pharmazeutische zusammensetzungen damit | |
EA200700166A1 (ru) | 4-замещённые производные хинолина, способ получения и промежуточные вещества для их приготовления и содержащие их фармацевтические композиции | |
DE60214990D1 (de) | Benzolsulfonsäureester-indol-5-yl als 5-ht6 rezeptor-antagonisten | |
GEP20125547B (en) | (aza) indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor | |
HK1081194A1 (en) | 6-amino-1h-indazole compounds as phosphodiesterase4 inhibitors, pharmaceutical compositions compris ing the same, and use thereof | |
NO20073725L (no) | CCI-779-polymorf og dens anvendelse | |
WO2005011609A3 (fr) | Composes tricycliques a base de triazolopurine et compositions pharmaceutiques contenant ces composes | |
WO2004075846A3 (fr) | Composes tricycliques a base de pyrazolopurine et compositions pharmaceutiques renfermant ces composes | |
UY29012A1 (es) | "oxazolididonas y composiciones y metodos relacionados" | |
RS50826B (sr) | Fungicidne kompozicije |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20090313 Year of fee payment: 6 |
|
OBST | Application withdrawn |